Talman Arthur auteur aut IRD Clain J. auteur aut IRD Duval Romain auteur aut IRD Menard R. auteur aut IRD Ariey F. auteur aut IRD text journalArticle eng text/pdf born digital access Artemisinin is the most widely-used compound against malaria and plays a critical role in the treatment of malaria worldwide. Resistance to artemisinin emerged about a decade ago in Southeast Asia and it is paramount to prevent its spread or emergence in Africa. Artemisinin has a complex mode of action and can cause widespread injury to many components of the parasite. In this review, we outline the different metabolic pathways affected by artemisinin, including the unfolded protein response, protein polyubiquitination, proteasome, phosphatidylinositol-3-kinase, and the eukaryotic translation initiation factor 2 alpha. Based on recently published data, we present a model of how these different pathways interplay and how mutations in K13, the main identified resistance marker, may help parasites survive under artemisinin pressure. specialized ASIE DU SUD EST 052 076 050 35 12 953-963 2019 1471-4922 https://www.documentation.ird.fr/hor/fdi:010077377 10.1016/j.pt.2019.09.005 1471-4922 [F B010077377] https://www.documentation.ird.fr/hor/fdi:010077377 https://www.documentation.ird.fr/intranet/publi/2019/12/010077377.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2020-01-07 2025-02-24 fdi:010077377 fre